We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » UCB Gets Six More Months of Exclusivity for Epilepsy Drug
UCB Gets Six More Months of Exclusivity for Epilepsy Drug
June 10, 2008
The FDA has granted Belgium-based pharmaceutical company UCB another six months of pediatric exclusivity for licensed indications of its epilepsy drug Keppra, through Jan. 14, 2009.